Oryzon to partner before market entry
Spanish biopharmaceutical company Oryzon develops epigenetic personalized medicines for patients with cancer and CNS disorders. BioStock met with CEO Carlos Buesa at this week’s BIO-Europe conference. He talked about their plans to pursue a phase III trial in Borderline Personality Disorder, and, as for the conference, he eluded to multiple interactions with potential partners.